MCID: MST016
MIFTS: 28

Mesothelioma, Somatic malady

Genetic diseases, Rare diseases, Cancer diseases categories

Aliases & Classifications for Mesothelioma, Somatic

About this section

Aliases & Descriptions for Mesothelioma, Somatic:

Name: Mesothelioma, Somatic 46
Malignant Mesothelioma 8 42 10 44 61
Malignant Mesothelioma, Susceptibility to 9 22
Asbestos-Related Malignant Mesothelioma 8 61
Advanced Malignant Mesothelioma 8 61
 
Mesothelioma, Malignant 46 42
Malignant Tumor of Mesothelium 8
Mesothelioma Diffuse Malignant 44
Diffuse Malignant Mesothelioma 8


Classifications:



External Ids:

OMIM46 156240
Disease Ontology8 DOID:1790
NCIt39 C7865
SNOMED-CT56 62064005
MeSH33 D008654
ICD9CM27 163

Summaries for Mesothelioma, Somatic

About this section
OMIM:46 Malignant mesothelioma is an aggressive neoplasm of the serosal lining of the chest etiologically linked to asbestos.... (156240) more...

MalaCards based summary: Mesothelioma, Somatic, also known as malignant mesothelioma, is related to leukemia and mesothelioma, and has symptoms including malignant mesothelioma An important gene associated with Mesothelioma, Somatic is WT1 (Wilms tumor 1). The compound serine have been mentioned in the context of this disorder. Related mouse phenotype embryogenesis.

Disease Ontology:8 A cell type cancer that has material basis in mesothelial tissue.

Related Diseases for Mesothelioma, Somatic

About this section

Graphical network of the top 20 diseases related to Mesothelioma, Somatic:



Diseases related to mesothelioma, somatic

Symptoms for Mesothelioma, Somatic

About this section

Symptoms by clinical synopsis from OMIM:

156240

Clinical features from OMIM:

156240

HPO human phenotypes related to Mesothelioma, Somatic:

id Description Frequency HPO Source Accession
1 malignant mesothelioma HP:0100001

Drugs & Therapeutics for Mesothelioma, Somatic

About this section

FDA approved drugs:

id Drug Name Active Ingredient(s)13 Pharmaceutical Company Approval Date
1
Alimta13 38 PEMETREXED (also Pemetrexed Disodium) Eli Lilly Approved February 2004
FDA Label: Alimta
Malady that Drug Treats: Mesothelioma
Indications and Usage:13 ALIMTA┬«; is a folate analog metabolic inhibitor indicated for:; Locally Advanced or Metastatic Nonsquamous Non-Small Cell; Lung Cancer:; Initial treatment in combination with cisplatin. (1.1); Maintenance treatment of patients whose disease has not; progressed after four cycles of platinum-based first-line; chemotherapy. (1.2); After prior chemotherapy as a single-agent. (1.3); Mesothelioma: in combination with cisplatin. (1.4); Limitations of Use:; ALIMTA is not indicated for the treatment of patients with; squamous cell non-small cell lung cancer. (1.5)
DrugBank Targets:11 1. Thymidylate synthase; 2. Bifunctional purine biosynthesis protein PURH; 3. Dihydrofolate reductase; 4. Trifunctional purine biosynthetic protein adenosine-3
Mechanism of Action:13 
Target: folic acid/ thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase
Action: antagonist/ inhibitor
FDA: ALIMTA, pemetrexed for injection, is a folate analog metabolic inhibitor that exerts its action by disrupting folatedependent; metabolic processes essential for cell replication. In vitro studies have shown that pemetrexed inhibits; thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT),; which are folate-dependent enzymes involved in the de novo biosynthesis of thymidine and purine nucleotides.; Pemetrexed is taken into cells by membrane carriers such as the reduced folate carrier and membrane folate binding; protein transport systems. Once in the cell, pemetrexed is converted to polyglutamate forms by the enzyme; folylpolyglutamate synthetase. The polyglutamate forms are retained in cells and are inhibitors of TS and GARFT.; Polyglutamation is a time- and concentration-dependent process that occurs in tumor cells and, is thought to occur to a; lesser extent, in normal tissues. Polyglutamated metabolites are thought to have an increased intracellular half-life; resulting in prolonged drug action in malignant cells.

Drug clinical trials:

Search ClinicalTrials for Mesothelioma, Somatic

Search NIH Clinical Center for Mesothelioma, Somatic

Genetic Tests for Mesothelioma, Somatic

About this section

Genetic tests related to Mesothelioma, Somatic:

id Genetic test Affiliating Genes
1 Mesothelioma, Malignant22

Anatomical Context for Mesothelioma, Somatic

About this section

Animal Models for Mesothelioma, Somatic or affiliated genes

About this section

MGI Mouse Phenotypes related to Mesothelioma, Somatic:

35
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053809.1WT1, BCL10

Publications for Mesothelioma, Somatic

About this section

Variations for Mesothelioma, Somatic

About this section

Expression for genes affiliated with Mesothelioma, Somatic

About this section
Search GEO for disease gene expression data for Mesothelioma, Somatic.

Pathways for genes affiliated with Mesothelioma, Somatic

About this section

Compounds for genes affiliated with Mesothelioma, Somatic

About this section
Sources:
44Novoseek
See all sources

Compounds related to Mesothelioma, Somatic according to GeneCards Suite gene sharing:

idCompoundScoreTop Affiliating Genes
1serine449.1WT1, BCL10

GO Terms for genes affiliated with Mesothelioma, Somatic

About this section

Biological processes related to Mesothelioma, Somatic according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1positive regulation of transcription, DNA-templatedGO:00458939.1WT1, BCL10

Sources for Mesothelioma, Somatic

About this section
2CDC
12ExPASy
13FDA
14FMA
22GTR
23HGMD
24HMDB
25ICD10
26ICD10 via Orphanet
27ICD9CM
28IUPHAR
29KEGG
33MeSH
34MESH via Orphanet
35MGI
38NCI
39NCIt
40NDF-RT
43NINDS
44Novoseek
46OMIM
47OMIM via Orphanet
51PubMed
52QIAGEN
57SNOMED-CT via Orphanet
61UMLS
62UMLS via Orphanet